Business Context and Reporting Period
Company: Alterity Therapeutics Ltd (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2020 (Specific event date: December 16, 2020)
Principal Executive Offices: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate transaction rather than periodic financial performance.
Transaction Details:
- Agreement: Amendment No. 2 to the At Market Issuance Sales Agreement.
- Counterparties: B. Riley Securities, Inc. and JonesTrading Institutional Services LLC.
- Offering Capacity: Up to $50,000,000 of American Depositary Shares (ADSs).
- Commission Rate: Fixed rate of up to 3.0% of the gross sales price per share sold.
- Registration Basis: Issued pursuant to effective Registration Statement on Form F-3 (File No. 333-249311).
Material Changes
The primary material change is the execution of an amendment to the existing Sales Agreement dated October 16, 2016 (as previously amended in 2017). This amendment facilitates the sale of up to $50 million in ADSs through an "at the market offering" as defined in Rule 415 of the Securities Act Regulations.
Guidance, Outlook, and Risks
Management Commentary: The Company has provided customary indemnification rights to the Agents. Sales will be conducted based upon the Company's instructions.
Risks and Contingencies:
- Legal Restrictions: The report does not constitute an offer to sell or solicitation of an offer to buy in any state where such offer would be unlawful prior to registration or qualification.
- Development Stage: The Company is identified as a development stage enterprise, implying no current commercial revenue stream.
Investor Verification Checklist
- Verify the terms of Amendment No. 2 filed as Exhibit 1.3 to this report.
- Review the Prospectus Supplement filed on December 16, 2020, for specific offering details.
- Confirm the status of the Form F-3 Registration Statement (File No. 333-249311) referenced for share issuance.
- Check the Opinion of Counsel (Exhibit 5.1) regarding the validity of the shares to be issued.
- Monitor future filings for actual sales volumes and proceeds generated under the amended agreement.